Wegovy for Binge Eating Disorder: What the Evidence Actually Shows

Does Wegovy have an FDA approval for binge-eating disorder?

No. The Wegovy injection label (effective 18 June 2026), used with a reduced-calorie diet and more physical activity, covers three things: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining weight loss in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; and treating noncirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3) in adults, under accelerated approval [1]. Binge-eating disorder is not among them, so semaglutide given specifically to treat BED is off-label.

The same label says that using Wegovy with another semaglutide-containing product, or with any other GLP-1 receptor agonist, is not recommended [1].

What the semaglutide evidence in BED actually consists of

The direct clinical report is a retrospective, open-label cohort by Richards and colleagues in Obesity Pillars (2023) [2]. Patients were grouped by prescription: semaglutide alone, lisdexamfetamine or topiramate, or semaglutide combined with one of those drugs [2]. The semaglutide-only group showed greater reductions in Binge Eating Scale scores than the other groups; combining semaglutide with another drug did not produce greater reductions than semaglutide alone [2]. The pattern was similar in patients with moderate or severe BED and in the full sample [2]. The authors concluded that the effects of semaglutide in BED warrant further investigation [2].

That design cannot establish cause and effect. Treatment was not assigned at random, the study was open-label, and the measured outcome was a change in a symptom scale [2]. What the cohort supports is a hypothesis worth testing, not a treatment protocol.

The one randomized GLP-1 trial in BED used a different drug

Allison and colleagues (Obesity Science and Practice, 2023) ran a 17-week, double-blind, randomized pilot of liraglutide 3.0 mg daily versus placebo in 27 adults with BED and a BMI of at least 27 [3]. Objective binge episodes per week fell by 4.0 with liraglutide and 2.5 with placebo, a difference that was not statistically significant (p=0.37) [3]. BED remission was 44% versus 36%, respectively [3]. Weight loss was significantly greater with liraglutide, 5.2% versus 0.9% (p=0.005) [3]. The investigators reported a pharmacy medication dispensing error as a significant limitation and said more research on liraglutide and other GLP-1 receptor agonists in BED is warranted [3].

Liraglutide is a different GLP-1 receptor agonist, so these findings do not establish an effect for Wegovy [3].

Why weight loss is not a BED outcome

The liraglutide pilot makes the split visible: weight differed significantly between groups while the change in weekly binge episodes did not [3]. In the semaglutide cohort the reported outcome was Binge Eating Scale score, not weight [2], and a symptom score is not the same as remission of a diagnosis.

What does have guideline support for BED

The 2023 World Federation of Societies of Biological Psychiatry (WFSBP) guideline update recommends lisdexamfetamine (level of evidence A, grade of recommendation 1) or topiramate (level of evidence A, grade 1) for binge-eating disorder [4]. Lisdexamfetamine is the only pharmacotherapy FDA-approved for BED [2]. Topiramate is used off-label, and the WFSBP authors note that neither olanzapine nor topiramate has received marketing authorisation for an eating disorder from any regulatory agency [4]. That guideline update addresses drug treatment only.

Is there a BED-specific Wegovy dose?

The Wegovy label gives no dose for BED, because BED is not an indication [1]. Its schedules are written for the approved uses: 0.25 mg weekly for weeks 1 to 4, titrating every 4 weeks to a 2.4 mg maintenance dose from week 17 for weight reduction and cardiovascular risk reduction, with up to 7.2 mg weekly for adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss [1].

What the Wegovy label lists as risks

In pooled trials of 2,116 adults on Wegovy 2.4 mg and 1,261 on placebo, nausea occurred in 44% versus 16%, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%; 6.8% versus 3.2% stopped treatment because of adverse reactions [1]. The label also describes acute pancreatitis (it says to discontinue Wegovy if pancreatitis is suspected), acute gallbladder disease (cholelithiasis in 1.6% versus 0.7% of adults in weight-management trials), acute kidney injury from volume depletion, hypoglycemia when Wegovy is combined with insulin or an insulin secretagogue, and pulmonary aspiration during general anesthesia or deep sedation [1]. It says Wegovy is not recommended in patients with severe gastroparesis [1].